News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sepracor, Inc. (SEPR): BROVANA™ Inhalation Solution Study Data Presented at American College of Chest Physicians Annual Conference



10/25/2007 1:34:35 PM

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) today announced that it presented safety and efficacy data from several studies of BROVANA™ (arformoterol tartrate) Inhalation Solution at CHEST 2007, the annual meeting of the American College of Chest Physicians, in Chicago. The Effect of Twice-Daily Nebulized Arformoterol on QTC in Subjects With COPD This four-week, placebo-controlled, randomized, double-blind, multicenter, parallel-group, dose-ranging study evaluated changes in QTc interval in patients with chronic obstructive pulmonary disease (COPD) who were administered arformoterol at various doses, or placebo. Patients were divided into Part A (n=215) and were administered arformoterol 5 mcg, 15 mcg, or 25 mcg or placebo twice daily for two weeks, and subsequently re-randomized in Part B (n=191) and administered arformoterol 15 mcg, 25 mcg, or 50 mcg or placebo once daily for two weeks. Two models were used to calculate QTc from results of electrocardiograms (ECGs) for each of the patients in the study. Based on the data analyzed in this study, dosing with arformoterol did not prolong cardiac repolarization.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES